Meeting
2023 ASCO Genitourinary Cancers Symposium
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Authors
Nirmish Singla
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD
Nirmish Singla , Thomas Nirschl , Aleksandar Obradovic , Eugene Shenderov , Kara A. Lombardo , Xiaopu Liu , Alice Pons , Jelani Zarif , Steven P. Rowe , Bruce J. Trock , Hans J. Hammers , Trinity Bivalacqua , Phillip Pierorazio , Julie S. Deutsch , Tamara L. Lotan , Janis M. Taube , Yasser Ged , Michael A. Gorin , Mohamad E. Allaf , Charles G. Drake
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02575222
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 708)
DOI
10.1200/JCO.2023.41.6_suppl.708
Abstract #
708
Poster Bd #
K3
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.
First Author: Maria Isabel Carlo
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde
Poster
2018 Genitourinary Cancers Symposium
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
First Author: Lauren Christine Harshman
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Baseline circulating myeloid-derived suppressor cells and response to PD-1 inhibitor in non-small cell lung cancer patients.
First Author: Myriam Delaunay